3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
294
Carcinoma, Renal Cell
103
Urinary Bladder Neoplasms
82
Breast Neoplasms
51
Carcinoma, Transitional Cell
38
Melanoma
36
Kidney Neoplasms
35
Carcinoma, Non-Small-Cell Lung
32
Neoplasms
30
Neoplasm Metastasis
30
Ovarian Neoplasms
29
Colorectal Neoplasms
29
Sarcoma
25
Lung Neoplasms
24
Pancreatic Neoplasms
23
Stomach Neoplasms
21
Non-Muscle Invasive Bladder Neoplasms
21
Uterine Cervical Neoplasms
18
Wilms Tumor
17
Endometrial Neoplasms
17
Esophageal Neoplasms
15
Carcinoma, Hepatocellular
15
Squamous Cell Carcinoma of Head and Neck
14
Adenocarcinoma
14
Neuroblastoma
13
Head and Neck Neoplasms
12
Rhabdomyosarcoma
11
Rhabdoid Tumor
11
Osteosarcoma
11
Metastatic Castration-resistant Prostate Cancer
11
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
High-Risk Localized Prostate Cancer
×
Genitourinary
×
30 days
×
Clear all
NCT07450599
2026-05-13
CHINANEO
Bayer
Phase 2
Recruiting
250 enrolled